These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28727614)

  • 21. Mydriatic and cardiovascular effects of phenylephrine 2.5% versus phenylephrine 10%, both associated with tropicamide 1%.
    Motta MM; Coblentz J; Fernandes BF; Burnier MN
    Ophthalmic Res; 2009; 42(2):87-9. PubMed ID: 19478547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of an eye drop mixture for pupillary dilatation: A randomized comparative study.
    Bhurayanontachai P; Saengkaew S; Apiromruck P
    J Optom; 2017; 10(2):111-116. PubMed ID: 27321772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pupillographic evaluation of a phenylephrine HCl 5%-tropicamide 0.8% combination mydriatic.
    Kergoat H; Lovasik JV; Doughty MJ
    J Ocul Pharmacol; 1989; 5(3):199-216. PubMed ID: 2625616
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tropicamide 1% mydriatic effect: comparison between spray in closed eyes and eye drops in open eyes.
    Portes AJ; Barbosa AC; de Mello GL; Lopes MA; Cavalcanti RS
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):632-5. PubMed ID: 22775152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of mydriatic efficacy of spray application and drop instillation of tropicamide 1%.
    Akman A; Aydin P
    Eye (Lond); 1999 Oct; 13 ( Pt 5)():653-5. PubMed ID: 10696320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors Affecting Pupil Reactivity After Cycloplegia in Asian Children.
    Lim J; Chia A; Saffari SE; Handa S
    Asia Pac J Ophthalmol (Phila); 2019; 8(4):304-307. PubMed ID: 31385819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the utility of 2.5% phenylephrine for diagnostic pupillary dilation.
    Liu JC; Green W; Van Stavern GP; Culican SM
    Can J Ophthalmol; 2017 Aug; 52(4):349-354. PubMed ID: 28774515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of commercial dilating agents on laser flare-cell measurements.
    Chin PK; Cuzzani OE; Gimbel HV; Sun R
    Can J Ophthalmol; 1996 Dec; 31(7):362-5. PubMed ID: 8971457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dosing problems in the use of topical ophthalmic drops.
    Loewenstein A; Geyer O; Blanc A; Lazar M
    Graefes Arch Clin Exp Ophthalmol; 1992; 230(4):378-9. PubMed ID: 1505772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of efficacy and tolerance between 1% hydroxyamphetamine plus 0.25% tropicamide (Paremyd) and 0.5% tropicamide combined with 2.5% phenylephrine.
    Zeise MM; McDougall BW; Bartlett JD; Corliss D; Mitten L
    J Am Optom Assoc; 1996 Nov; 67(11):681-9. PubMed ID: 8979662
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is it necessary to wait several minutes between applications of different topical ophthalmic solutions? A preliminary study with tropicamide eye drops in healthy dogs.
    Arad D; Deckel R; Pe'er O; Ross M; Sebbag L; Ofri R
    Vet Ophthalmol; 2021 Jul; 24(4):374-379. PubMed ID: 34402570
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effective degree of mydriasis with phenylephrine and tropicamide.
    Levine L
    Am J Optom Physiol Opt; 1976 Dec; 53(12):774-85. PubMed ID: 1015526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Serious adverse side effects after pupillary dilation in preterm infants].
    Lux AL; Mouriaux F; Guillois B; Fedrizzi S; Peyro-Saint-Paul L; Denion E
    J Fr Ophtalmol; 2015 Mar; 38(3):193-8. PubMed ID: 25726252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of a mydriatic spray in the pediatric population.
    Benavides JO; Satchell ER; Frantz KA
    Optom Vis Sci; 1997 Mar; 74(3):160-3. PubMed ID: 9159806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effectiveness of mydriasis by two instillation methods of combined 0.75% tropicamide and 2.5% phenylephrine eye drop in preterm infants.
    Phamonvaechavan P; Chutasmit K; Damrongrak P; Koukiatkul S; Wongkiatkajorn T; Ngerncham S
    J Med Assoc Thai; 2012 Apr; 95 Suppl 4():S1-7. PubMed ID: 22696845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects on pupil size and accommodation of sympathetic and parasympatholytic agents.
    Paggiarino DA; Brancato LJ; Newton RE
    Ann Ophthalmol; 1993 Jul; 25(7):244-9, 253. PubMed ID: 8363290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of dilute drug solutions for routine cycloplegia and mydriasis.
    Brown C; Hanna C
    Am J Ophthalmol; 1978 Dec; 86(6):820-4. PubMed ID: 736080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison between obtained mydriasis in type 2 diabetics and non-diabetic patients.
    Coblentz J; Motta MM; Fernandes BF; Burnier MN; Vianna RN
    Curr Eye Res; 2009 Nov; 34(11):925-7. PubMed ID: 19958108
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optical coherence tomography quantitative analysis of iris volume changes after pharmacologic mydriasis.
    Aptel F; Denis P
    Ophthalmology; 2010 Jan; 117(1):3-10. PubMed ID: 19923002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of three madriatics on the human ocular aberrations].
    Yu J; Chen H; Hu JY; Xun PC
    Zhonghua Yan Ke Za Zhi; 2005 Sep; 41(9):826-31. PubMed ID: 16191351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.